FBIO Stock — Fortress Biotech Inc

Fortress Biotech Inc (FBIO)

Updated October 16, 2026.

FBIO is a Stock. Total return is -98.9% over the past 14.9 years, 810.6 points behind SPY at 711.7%.

Fortress Biotech is a biopharmaceutical company developing and commercializing treatments for dermatological, pain management, and oncological conditions. The company markets several approved therapies including Emrosi and Zilxi for rosacea, Qbrexza for hyperhidrosis, and various acne treatments, while advancing a pipeline of candidates in clinical development for conditions including gout, amyloidosis, and certain cancers. The company does not currently have an established distribution schedule.

FBIO performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.9% over the past 14.9 years, 810.6 points behind SPY at 711.7%. Over the past year its total return — price change plus distributions reinvested — is -31.7%. Its deepest 1-year drawdown was 57.3%.

FBIO key facts

Asset type

Stock

Asset class

Equity

Inception date

11/17/2011

Distribution frequency

None

Last close

$1.87 (as of 2026-10-16)

Market cap

$62,366,357

Average volume

264318.0

Beta

1.248

Payout ratio

0.0%

P/E ratio

0.68

Forward P/E

1.232

EPS

$2.76

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FBIO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.3%.

Who may consider FBIO — and who may not

It is a weaker fit for investors who need monthly cash flow (FBIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on FBIO

• All tickers starting with F

Tagged: Healthcare.

Frequently asked questions